Factors Associated With Complicated Pneumonia in Paedatrics

Sponsor
Assiut University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05792904
Collaborator
(none)
50
13

Study Details

Study Description

Brief Summary

Detecting Factors associated with complicated pneumonia in pediatrics

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Community acquired pneumonia is the cause of morbidity and mortality in children worldwide ,complication of Community acquired pneumonia in paedatrics include para -pneumonic pleural effusion ,empyema, necrotizing pneumonia and lung abscess.( Sawicki GS,2008) Pediatric para-pneumonic pleural effusion and empyema are considered different stages of the same pathophysiological process in which pleural inflammation causes fluid to accumulate in the pleural cavity, Necrotizing pneumonia results from pulmonary necrosis and tissue liquefaction. ( Ira Erlichman, MD,2017) Recent reports have characterized the clinical presentation of this complication and have shown favorable outcomes in children.( Sawicki GS,2008) Complicated pneumonia was defined as clinical pneumonia and the presence of pleural effusion, empyema (EMP) or Para-pneumonic childhood EMP was defined as the presence of pus (purulent fluid and/or WBC count>5,000 permm3) or bacteria in the pleural fluid.

    PPE was defined by pleural fluid not fitting criteria of EMP and the diagnosis of NP was made by the presence of multiple cavity gas-filled spaces within a pulmonary consolidation on chest X-rays or liquefaction of lung tissue according to CT scans as reviewed by a pediatric radiologist .( Ira Erlichman, MD 2017) Among patients with pneumonia AS MANY AS half may develop pleural effusions (i.e., fluid in THE PLEURAL SPACE); of these, 5-10 % MAY DEVELOP EMPYEMAN Ingeneral , "complicated pneumonia" refers to pneumonia accompanied by pleural effusion.( Byington CL,2010) Empyema is a serious COMPLICATIO characterized by pus and bacteria in the pleural space which may progress to necrosis, cavitation, or fistulas in the thoracic cavity. S. pneumoniae is the most common cause of complicated pneumonia in children (an M. A. Fletcher ETT 2014) Empyema among children age below 19 years in Utah (USA) (1994-2007)] and Australia(1998-2010)ranged from 0.9 to 12.5 per 100,000 (Byington CL,2010)the incidence was highest in children aged 0-4 and tend to increase over time. (Strachan RE,2013).

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    50 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Factors Associated With Complicated Pneumonia in Paedatrics
    Anticipated Study Start Date :
    Mar 1, 2023
    Anticipated Primary Completion Date :
    Apr 1, 2024
    Anticipated Study Completion Date :
    Apr 1, 2024

    Outcome Measures

    Primary Outcome Measures

    1. patients will be assessed by complete blood count [Baseline]

    2. C-reactive protein level [Baseline]

    3. Chest x-ray or CT chest image [Baseline]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    2 Months to 16 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Patient admitted at AUCH aged 2months up to 16 years old with sign and synptoms suggestive of pneumonia.
    Exclusion Criteria:
    • Immunodefiecency

    • Hematological And Malignancy.

    • NEONATAL PEROID.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • Assiut University

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Marim Sedky Sedeek Ali, Factors associated with complicated pneumonia in paedatrics, Assiut University
    ClinicalTrials.gov Identifier:
    NCT05792904
    Other Study ID Numbers:
    • Complicated pneumonia
    First Posted:
    Mar 31, 2023
    Last Update Posted:
    Mar 31, 2023
    Last Verified:
    Mar 1, 2023
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Mar 31, 2023